WO2025134062 - IONIZABLE LIPIDS
National phase entry is expected:
Publication Number
WO/2025/134062
Publication Date
26.06.2025
International Application No.
PCT/IB2024/063052
International Filing Date
20.12.2024
Title **
[English]
IONIZABLE LIPIDS
[French]
LIPIDES IONISABLES
Applicants **
BIONTECH DELIVERY TECHNOLOGIES GMBH
STUDIENGESELLSCHAFT KOHLE GGMBH
Inventors
PANZNER, Steffen
PREUSS, Arne
LIST, Benjamin
DE, Chandra Kanta
DEHN, Stefanie
ZHU, Chendan
SAMSONOWICZ-GÓRSKI, Jan
Priority Data
63/613,653
21.12.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3568 | |
| EPO | Filing, Examination, Granting | 28070 | |
| Japan | Filing, Examination, Granting | 3258 | |
| South Korea | Filing, Examination, Granting | 4213 | |
| USA | Filing, Examination, Granting | 13140 |
Total:
52,249
Contact Us
Abstract[English]
The present disclosure provides, among other things, a compound of formula I, or a pharmaceutically acceptable salt thereof, and uses thereof.[French]
La présente divulgation concerne, entre autres, un composé de formule I, ou un sel pharmaceutiquement acceptable de celui-ci, et ses utilisations.